Introduction
Barriers toward insulin therapy have been associated with easily avoidable challenges related to clinicians, patients, and health-care system in diabetes management. 1, 2 However, insulin omission/nonadherence and the consequent prolonged periods of poor glycemic control have been closely linked to negative clinical outcomes, including increased severity and progression of diabetic complications. [3] [4] [5] [6] Although data from the multinational The Global Attitudes of Patients and Physicians in Insulin Therapy (GAPP) survey revealed that insulin omission/nonadherence was reported to be highest in Turkey, followed by the USA, the People's Republic of China, and Japan, and lowest in France, Germany, UK, and Spain, 4, 7 no countryspecific data are available in Turkey considering the adherence to insulin therapy and reasons for treatment withdrawal in insulin-naïve type 2 diabetes patients.
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This multicenter study was designed to evaluate the impact of single vs sequential telephonic interviews on shortterm adherence to insulin treatment in insulin-naïve type 2 diabetes patients initiated on different insulin regimens.
Methods
study population
A total of 1,456 insulin-naïve patients with type 2 diabetes (mean [standard deviation (SD)] age: 56.0 [12. 0] years, 49.1% were females) initiated on insulin therapy were recruited from 13 tertiary care centers across Turkey in this 12 -week open-label randomized multicenter study conducted between October 2012 and April 2013. All type 2 diabetes outpatients who were referred to a diabetes education nurse to be trained on insulin treatment were included in the study, provided that they were aged 18-70 years, diagnosed with type 2 diabetes for at least 1 year, and were insulin naïve. Patients with type 1 diabetes, gestational diabetes, ongoing insulin treatment, or insulin use within the last 3 months were excluded from the study. All patients were initiated on insulin pen therapy and trained on insulin treatment and use of insulin pen by the same registered nurse. A total of five patients with treatment switching were not subjected to subgroup analyses.
Written informed consent was obtained from each subject following a detailed explanation of the objectives and protocol of the study, which was conducted in accordance with the ethical principles stated in the Declaration of Helsinki and approved by the Marmara University Faculty of Medicine's Ethics Committee.
Data collection
Baseline enrollment visit (day 0) was performed at the time of insulin initiation during insulin education in all patients who met the inclusion criteria. Afterward, patients were consecutively randomized to sequential (n=733, four repeated follow-up interviews on day 15, day 30, day 60, and day 90) and single (n=723, single follow-up interview at day 90) telephonic interview groups, depending on the schedule of phone interviews given during a 3-month follow-up.
Data on patient demographics (age and sex), educational status, and concerns about insulin treatment (efficacy in blood glucose lowering and risk of weight gain, hypoglycemia, painful injection, and becoming insulin dependent) were recorded at baseline enrollment visit via face-to-face interviewing.
Data During phone interviews, data on adherence to insulin treatment, insulin administration practice (self-injection or not), problems related to injection administration (discomfort/pain/itching at injection site), and blood glucose values measured within the last 15 days were recorded for all patients with no interference in insulin treatment. Routine follow-up of all patients was performed by their physicians who initiated the insulin regimen. Mean values for FBG and PPBG were calculated based on self-reported measurements in the past 15 days, as were HbA1c values. The reasons for treatment withdrawal (problems related to injection administration [discomfort/pain/itching at injection site], hypoglycemic events, normalization of blood glucose levels, at physicians' discretion, influence of family members and friends, workload/workplace conditions, weight gain, challenges in drug procurement, and allergic side effects) were recorded for discontinuers, while type and dosage of ongoing insulin treatment, dose adjustments, hypoglycemic events, skipping an injection for at least once in the last 15 days, the number of skipped doses, and most commonly skipped dose (morning/noon/evening/nighttime) in the last 15 days were recorded for continuers.
study parameters
Baseline demographic and clinical characteristics, baseline and third month glycemic, anthropometric, and treatmentrelated characteristics and insulin doses, third month rates for treatment adherence and skipping doses, and reported hypoglycemia frequency were evaluated with respect to interview groups and insulin regimen. Third month glycemic and anthropometric parameters were also evaluated according to skipping doses in continuers, while reasons for treatment discontinuation were identified in discontinuers. Patients' view on insulin therapy before and after treatment initiation was recorded. Logistic regression analysis was performed for factors predicting higher persistence and increased likelihood of skipping an injection.
statistical analysis
Statistical analysis was made using computer software (GraphPad InStat 3.0; GraphPad Software, Inc., San Diego, CA, USA). Chi-square (χ 2 ) test was used for the comparison 
Treatment adherence
Overall 1,114 (76.8%) patients remained on insulin treatment at the third month of study, treatment withdrawal occurred in 225 (15.5%) patients and 112 (7.7%) patients could not be accessed (Table 2 ).
In the sequential interview group, persistence rates were 94.1% on day 15, 90.0% on day 30, and 89.2% on day 60. Sequential rather than single telephonic interview was associated with significantly higher persistence (83.2% vs 70.3%, P0.001) and less inability to access patients (2.9% vs 12.6%, P0.001). No significant difference was noted in persistence rates with respect to insulin regimen (76.9% in basal bolus, 78.6% in premixed, and 74.1% in basal insulin groups) ( Table 2) .
Basal bolus (83.0% vs 69.3%, P0.0001) and basal insulin (84.8% vs 62.8%, P0.0001) regimens were associated with higher persistence rates in the case of sequential rather than single telephonic interview, while persistence rates were similarly high in sequential (81.9%) and single (75.8%) interview groups receiving premixed insulin regimen. In the sequential interview group, similar persistence rates were noted with respect to different insulin regimens, whereas in the single interview group, higher persistence was noted in patients receiving premixed regimen (75.8%) than in basal insulin (62.8%) regimen (P0.05) ( Table 2) .
reasons for treatment withdrawal Accordingly, treatment withdrawal was identified to be mostly at the patient's discretion (57.3%, n=71), followed 
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Yavuz et al by being at physicians' discretion (25.0%, n=31). Drug side effects (4.8%, n=6), influence of patient's family/environment (0.8%, n=1), problems related to drug procurement (0.8%, n=1) or health-care system (0.8%, n=1) were the other reasons for treatment withdrawal, while death occurred in 13 patients (10.5%). Reasons for patients to decide to discontinue treatment were normalization of blood glucose (30.6%), influence of family members and friends (10.5%), allergic side effects (4.8%), problems related to workload/workplace environment (6.4%), and drug procurement (4.0%).
skipping doses
Overall 186 out of 878 patients (21.2%) at the third month identified that they skipped doses with no significant difference between sequential and single interview groups (21.4% and 21.9%, respectively, P=0.830), whereas there was a significantly higher rate for skipping doses in basal bolus than in premixed and basal insulin regimens (27.0% vs 15.0% and 15.8%, respectively, P0.0001). Among 154 patients with available data, noon and evening doses (23.1% for each) were the most commonly skipped doses, followed by morning dose (18.8%), nighttime dose (13.4%), and all doses (4.3%). At the end of the third month, significantly higher mean (SD) 
insulin doses
No significant change was noted in insulin doses at baseline and third month in sequential vs single interview groups (Table 3) .
Among the three types of insulin regimens, basal insulin was associated with the lowest total daily insulin dose both at baseline (14.7 [6.5] 
Patients' view on insulin therapy
Before insulin treatment initiation, 47.8% of patients considered insulin treatment positively, while negative beliefs were identified in 29.1% of patients before treatment. Major concerns about the insulin treatment were about the painful injections (36.7%), risk of becoming insulin dependent (32.4%), risk of hypoglycemia (25.0%), and weight gain (22.1%), while 85.1% of patients considered insulin to be an effective agent in blood glucose lowering (Table 6) .
At the third month of insulin treatment, self-injection with insulin pen was identified by 56.2% of patients, which was considered to be a painless procedure by 59.1% and identified to be associated with itching (2.2%) or hives/swelling (1.2%) at the injection site by a few patients (Table 6 ).
Factors predicting treatment persistence and skipping an injection
Logistic regression analysis with persistence as the dependent variable revealed that longer diabetes duration (OR, 
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Logistic regression analysis with skipping an injection as the dependent variable revealed that basal bolus regimen (OR, 1.583; 95% CI, 1.011-2.479; P=0.045) and higher HbA1c levels (OR, 1.114; 95% CI, 1.028-1.207; P=0.008) were associated with increased likelihood of skipping an injection. Age, sex, diabetes duration, initial concerns about insulin therapy, and frequency of telephonic interview were not among the significant predictors of higher persistence ( Table 7 ).
Discussion
Our findings in a Turkish cohort of insulin-naïve patients with type 2 diabetes initiated on different insulin regimens at tertiary health-care centers revealed a dropout rate of 15.5% and skipping an insulin dose in 21.2% of patients, leading to an overall nonadherence rate of 36.7% within 3 months.
Poor patient adherence in insulin therapy has also been consistently reported worldwide, ranging from 19.9% in France to 42% in the USA and 44% in Japan. [6] [7] [8] [9] According to multinational GAPP survey, among participating countries, insulin omission/nonadherence was reported to be highest in Turkey, followed by the USA, the People's Republic of China, and Japan, and lowest in France, Germany, UK, and Spain. 4, 7 One in three insulin-naïve patients initiating insulin have been indicated to never become ongoing users, 10 with missing an injection in almost 60% of patients and missing doses on a regular basis in 20% 11 and 16%-49% of persistence reported at 6-12 months. 12, 13 Our previous findings in a cohort of 433 patients with insulin-naïve type 2 diabetes initiated on insulin therapy revealed poor persistence to insulin therapy, particularly in patients under basal bolus regimen, while negative perceptions about insulin therapy seemed to be the main cause for poor adherence. 14 Similarly, having less negative appraisal of insulin therapy was among the significant determinants of higher persistence in our cohort. This seems in agreement with the suggestion of increased likelihood of treatment acceptance in the case of having less negative appraisal of insulin treatment than having more objections against this treatment option. 15 Hence, identification of negative appraisal of insulin therapy in one-third of patients prior to treatment initiation seems notable. (24) 90 (23) 66 (18) 66 (18) 100 (25) 91 (22) 83 (22) 69 (20) 65 (16) 65 (16 
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Telephonic interviews and insulin adherence
In this regard, better persistence rates in our patients who had sequential rather than single telephonic interview during their follow-up, despite no interference in treatment during interviews, seems to indicate the help of effectively continued communication in overcoming negative appraisal of treatment and thus achievement of better compliance with the insulin regimens. Additionally, implementation of follow-up via telephonic interviews made by physicians who initiated the insulin regimen rather than through a nonspecific record system might also have a role in the better patient compliance.
Factors related to injection, complexity of the regimen, and more frequent and inflexible dosing schedules have been considered to be the key treatment-related barriers to insulin therapy. 13, [16] [17] [18] Similarly, major concerns about the insulin treatment were about the painful injections, risk of becoming insulin dependent, and risk of hypoglycemia and weight gain in our patients prior to treatment initiation. However, after treatment initiation, injections were reported to be painless by most of the patients. In addition, prior to treatment, 85.1% of our patients considered insulin to be an effective agent in blood glucose lowering, while normalization of blood glucose levels rather than injection-related problems become the main reason for treatment withdrawal at patients' discretion in our cohort.
Hence, our findings support that use of insulin pens may overcome some of the patient-related challenges including stigma and fear of initiation of insulin therapy 1, 19, 20 and 
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Yavuz et al strongly suggest the temporality rather than stability of barriers to insulin therapy with likely modifications in the initial negative appraisal after the initiation of insulin therapy. 15 Similarly, 3-month follow-up data on diabetes patients revealed increase in barriers to insulin therapy in patients kept on an oral regimen, whereas less negative appraisal of insulin treatment was reported in patients switched to insulin therapy. 15 In this regard, sequential (via four repeated follow-up interviews on days 15, 30, 60, and 90) rather than single (at day 90) telephonic interview seems to offer an option to enhance the flexibility of therapy, a better patient adherence, and ultimately, improved patient outcomes. 21, 22 Initiation of premixed or basal insulin regimens was associated with improved glycemic control in our patients with reduction in HbA1c levels (from baseline levels of 10.5% [2.0%] in premixed and 9.7% [2.0%] in basal insulin regimens to 8.1% [1.5%] at 3 months for both) without causing weight gain within the course of 3 months. This seems consistent with data from treat-to-target studies concerning efficacy of insulin regimens 1, 23, 24 as well as the similar efficacy reported for basal insulin and premixed insulin in lowering HbA1c, while a lower rate of hypoglycemia with basal insulin in the literature. 25 Data from a meta-analysis including 38,803 patients from 87 randomized clinical trials revealed a very strong positive relationship between baseline HbA1c and the magnitude of HbA1c change. 26 However, both baseline (mean 11.3%) and third month (mean 8.5%) HbA1c levels were significantly higher in insulin-naïve patients initiating basal bolus rather than initiating other regimens in our cohort. Besides, our findings revealed high HbA1c levels to be a significant predictor of both increased persistence and increased likelihood of skipping doses during 12 weeks, which may also be associated with identification of basal bolus regimen as significant predictor of higher likelihood of skipping doses in our cohort.
Given that anxiety and/or fear related to hypoglycemia in both patients and physicians can interfere with glycemic control, 1 higher rates for hypoglycemia observed with use of basal bolus than other insulin regimens also seems be associated with consequent poor glycemic control, despite use of higher insulin doses and the increased likelihood of skipping doses in patients initiating basal bolus regimen.
Notably, in GAPP survey, it was suggested based on patient and physician statements that an ideal regimen would minimize the number of injections required, the risk of hypoglycemia, and the consequences of a delayed or missed insulin dose. 4 Hence, while selected in younger patients with lesser diabetic complications in our cohort, initiating basal bolus regimen seems not to be an optimal therapeutic option in insulin-naïve patients with initially higher baseline HbA1c values. 
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Telephonic interviews and insulin adherence guidelines and recommendations may induce the clinical inertia observed among clinicians, 23, 30, 31 consideration of the guidelines within the context of a patient-centered approach by individualizing insulin therapy to a regimen that is compatible with the patient's glucose profile, as well as with the current information on evolving new insulin formulations, seems to be the best possible modality to overcome challenges to achieving glycemic control. 1, 32 The major strength of this open-label randomized multicenter study seems to be the inclusion of data on 1,456 insulin-naïve patients with type 2 diabetes at 13 centers in Turkey, which enables our findings likely to be generalizable based on the presence of a representative sample of the overall population. However, certain limitations to this study should be considered. First, our findings are based on self-reported medication adherence, which could be biased by patients' foreknowledge of their laboratory results. Lack of data on adherence to other aspects of the diabetes treatment such as diet and physical activity seems to be another limitation, which otherwise would extend the knowledge achieved in the current study. Nevertheless, despite these certain limitations, given the paucity of solid information available in this area, our findings represent a valuable contribution to the literature.
Conclusion
Our findings in a Turkish cohort of insulin-naïve patients with type 2 diabetes initiated on different insulin regimens revealed low adherence to insulin treatment in terms of drop out as well as skipping doses in a 3-month follow-up. Our findings indicate higher likelihood of persistence in the case of sequential rather than single telephonic interview with patients, higher likelihood of skipping an injection in the case of initiating basal bolus rather than other insulin regimens and increased rates for persistence while also skipping an injection in the case of poor glycemic control.
Indeed, given that sequential rather than single telephone interviews during follow-up were associated with higher persistence rates, and premixed and basal insulin regimens rather than basal bolus regimen were associated with lower rate of skipping an injection, follow-up of patients initiating basal bolus regimen based on single telephonic interview seems to be the least advantageous approach in the clinical care of insulin-naïve type 2 diabetes patients in terms of treatment adherence.
In addition, it should be noted that, in line with consideration of basal bolus regimen to be challenging for patients and physician due to complexity of implementation leading its underuse in patients with type 2 diabetes, 27 basal bolus regimen was the least commonly initiated (27.5%) insulin regimen in our cohort.
Improved glycemic control has been indicated to be judged only in the context of hypoglycemia incidence and insulin dose. 28 In this regard, basal insulin, as the regimen associated with lowest insulin doses and lowest rates of minor or major hypoglycemia along with lower rate of skipping an injection in our cohort, seems to offer a good alternative in insulin initiators. Indeed, higher rate of concomitant metformin treatment was noted in our patients initiating basal insulin than initiating other insulin regimens. This seems in accordance with the consideration of basal insulin plus oral antidiabetes drugs as a well-validated option to enhance insulin initiation, 29 while additional use of metformin may also have resulted in further improvement in glycemic control in these patients. 28 Notably, unlike the single interview of patients on basal bolus and basal insulin regimens, which revealed lower persistence rates compared with sequential interview, persistence rates were similar between single and sequential interview groups of patients initiating premixed regimen. Moreover, single interview revealed significantly higher persistence for patients initiating premixed than basal insulin regimen.
Use of insulin pen has been associated with lower rates of hypoglycemia, greater adherence and persistence, and thereby greater glycemic control. 1 In this regard, while all patients were on insulin pen therapy, identification of nonadherence in more than one-third of our cohort of patients with type 2 diabetes emphasizes further investigation of determinants of nonadherence to insulin therapy among Turkish patients with type 2 diabetes given the consequent poor clinical outcome. 3, 5, 6 Indeed, given that treatment discontinuation was based on physician decision in 25.0% of discontinuers, the role of physician-related factors in insulin adherence should also be emphasized. Since a lack of consensus among national
